Biofarmasi

Biopharmaceuticals are revolutionizing healthcare, offering targeted therapies for cancer, autoimmune diseases, and infectious conditions. Unlike traditional small-molecule drugs, biopharma products are complex macromolecules or living cells. Their stability and functionality depend on delicate interactions at the molecular and colloidal level.
Proteins, for example, can aggregate if their surface charge is insufficient to maintain repulsion. Aggregation reduces efficacy and may trigger immune responses. Vaccines require stable suspensions of antigens to remain effective during storage and transport. Cell-based therapies demand precise control of culture media and surface interactions.
DataPhysics Instruments provide tools to address these challenges. The ZPA 20 measures zeta potential, helping researchers understand protein stability and aggregation risks. The MultiScan system monitors dispersion stability, detecting early signs of destabilization in protein solutions or vaccine suspensions. The DCAT tensiometer evaluates interfacial tension, offering insights into how proteins interact with excipients or surfaces.
In R&D, these tools support formulation optimization, ensuring biopharma products remain stable and effective. In production, they provide quality assurance by delivering reproducible, automated measurements that comply with regulatory standards.
Biopharma is not just about producing drugs—it is about engineering complex biological systems that require precise control of interfacial and colloidal properties. DataPhysics Instruments empower researchers and manufacturers to achieve this control, driving innovation and patient safety.